510 reports of this reaction
1.4% of all ZIPRASIDONE reports
#17 most reported adverse reaction
OBESITY is the #17 most commonly reported adverse reaction for ZIPRASIDONE, manufactured by ROERIG. There are 510 FDA adverse event reports linking ZIPRASIDONE to OBESITY. This represents approximately 1.4% of all 36,171 adverse event reports for this drug.
ZIPRASIDONE has an overall safety score of 82 out of 100. Patients taking ZIPRASIDONE who experience obesity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OBESITY is a less commonly reported adverse event for ZIPRASIDONE, but still significant enough to appear in the safety profile.
In addition to obesity, the following adverse reactions have been reported for ZIPRASIDONE:
The following drugs have also been linked to obesity in FDA adverse event reports:
OBESITY has been reported as an adverse event in 510 FDA reports for ZIPRASIDONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OBESITY accounts for approximately 1.4% of all adverse event reports for ZIPRASIDONE, making it a notable side effect.
If you experience obesity while taking ZIPRASIDONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.